Olema Pharmaceuticals – LifeCareNews

LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283

Olema Oncology Reports Inducement Grants Under Nasdaq

SAN FRANCISCO, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and…

Olema Oncology Reports Third Quarter 2022 Financial Results

Presented preliminary results from OP-1250 Phase 1/2 dose expansion study demonstrating favorable tolerability, high drug exposure, and strong anti-tumor activity at the 34th EORTC-NCI-AACR SymposiumInitial clinical data for OP-1250 in…